[ad_1]
NEW YORK (Reuters Health) – A global pandemic alliance plans to invest up to $ 8.4 million to develop technology to produce industrial vaccines that are adaptable to all diseases, allowing to fight against many bacteria and viruses, such as the flu, Ebola and rabies.
The agreement between the Alliance for Pandemic Preparedness and a team of scientists from Imperial College London aims to develop a "vaccine platform" using a technology allowing the ribosome DNA, which represents a genome in a virus strain and allows them to clone and multiply This technique is known as "SA / RNA".
The vaccine platform uses basic ingredients and can be modified to immunize against various diseases by adding a new gene sequence of the target disease to prevent it.
"This could be a huge change, it could change the way we look at how vaccines are made," said Robin Shattuck, who heads the imperial team responsible for developing the system called RapidVAC.
He added that many years of research and testing were still needed, but he hoped that someday technology would produce vaccines that would be taken only once to prevent a single pandemic or to produce a vaccine. mixture of vaccines protected from several different infectious diseases at the same time.
The idea of the SA / RNA technique is to simulate the functioning of cells in the body to produce a disease-resistant serum, which involves the introduction of a foreign body stimulating an immune response instead of to inject the same serum directly to the body.
"The other benefit is that the production in this case will be very fast because the whole process is industrial," Shattuck said in a phone interview.
The emergence of an epidemic like Ebola in Africa or Zica, which has been launched from Brazil, occurs intermittently and unpredictably, and the situation is changing very rapidly. In contrast, the development of a vaccine for vaccination against these diseases currently lasts up to 10 years. Or more.
The Alliance for Pandemic Preparedness was formed in early 2017 to accelerate vaccine development, particularly against new diseases that have never been treated.
The alliance and the team hope to start testing the animals in the lab early next year, then move on to the first human clinical trials in two years time.
[ad_2]
Source link
